Research progress on the administration of nebulized budesonide for the prevention and treatment of bronchopulmonary dysplasia in preterm infants
10.3760/cma.j.cn113903-20240702-00483
- VernacularTitle:雾化吸入布地奈德防治早产儿支气管肺发育不良的研究进展
- Author:
Hongshan SHI
1
;
Bingjie WANG
1
;
Xiangyu GAO
1
Author Information
1. 徐州市中心医院（徐州医科大学徐州临床学院）新生儿科，徐州 221009
- Publication Type:Journal Article
- Keywords:
Bronchopulmonary dysplasia;
Budesonide;
Inhaled;
Premature infants
- From:
Chinese Journal of Perinatal Medicine
2025;28(2):162-166
- CountryChina
- Language:Chinese
-
Abstract:
Postnatal glucocorticoid has become an important measure for the prevention and treatment of bronchopulmonary dysplasia in preterm infants. Systemic application of glucocorticoids has therapeutical effectiveness but comes with significant side effects. Many studies have shown that nebulized budesonide may help prevent and treat bronchopulmonary dysplasia in preterm infants. However, there are no clear recommendations on the timing, route, dosage, and short- or long-term efficacy. Therefore, this paper reviews the research progress on the application of nebulized budesonide for the prevention and treatment of bronchopulmonary dysplasia in preterm infants.
